Published in Lancet on November 21, 1981
Double-blind randomised trial of Org 10172 low-molecular-weight heparinoid in prevention of deep-vein thrombosis in thrombotic stroke. Lancet (1987) 1.25
A study of methods of identification and estimation of Lp(a) lipoprotein and of its significance in health, hyperlipidaemia and atherosclerosis. Atherosclerosis (1974) 1.04
Glaucoma and ischaemic vascular disease risk factors. Trans Ophthalmol Soc U K (1976) 0.95
ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man. Br J Clin Pharmacol (1987) 0.91
Use of a heparinoid in patients with hemorrhagic stroke and thromboembolic disease. Ann Neurol (1984) 0.89
Peptide composition of human plasma apolipoproteins A, B and C. Expos Annu Biochim Med (1972) 0.83
Identification of lipoprotein families in familial lecithin: cholesterol acyltransferase deficiency. Biochim Biophys Acta (1973) 0.82
A method for the quantitative determination of the abnormal lipoprotein (LP X) of obstructive jaundice. Clin Chim Acta (1972) 0.82
Utilization of the quantitative assay of lipoprotein X in the differential diagnosis of extraphepatic obstructive jaundice and intrahepatic diseases. Gastroenterology (1976) 0.81
Orgaran in heparin-induced thrombocytopenia. Haemostasis (1992) 0.81
Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Haemostasis (1992) 0.79
Heparin-induced thrombocytopenia in paediatric patients--a review of the literature and a new case treated with danaparoid sodium. Eur J Pediatr (1999) 0.79
Apolipoproteins and lipoprotein families in familial lecithin: cholesterol acyltransferase deficiency. Scand J Clin Lab Invest Suppl (1974) 0.79
Danaparoid is not a low-molecular-weight heparin. Am J Hosp Pharm (1994) 0.78
Prevention of deep vein thrombosis following total hip replacement by low molecular weight heparinoid. Thromb Haemost (1992) 0.78
Interaction study between Org 10172, a low molecular weight heparinoid, and acetylsalicylic acid in healthy male volunteers. Thromb Haemost (1991) 0.77
Quantitative changes of serum lipoprotein-X after cholestyramine administration in infants with cholestatic biliary tract and liver disease. Eur J Clin Invest (1978) 0.77
[Danaparoid in pregnancy in cases of heparin intolerance - use in 59 cases]. Hamostaseologie (2007) 0.77
A novel assay for the quantitative determination of lipoprotein-X (LP-X) in serum. Clin Chim Acta (1983) 0.76
Antithrombotic therapy in acute ischaemic stroke: an overview of the completed randomised trials. J Neurol Neurosurg Psychiatry (1994) 0.75
Management of heparin induced thrombocytopenia. BMJ (1993) 0.75
A quantitative method for blood lipoproteins using cellulose acetate electrophoresis. J Clin Pathol (1971) 0.75
[Metabolic changes of cholestatic lipoprotein (LP-X) in the diagnosis of biliary atresia]. Cesk Pediatr (1978) 0.75
Early clinical experience of a new heparinoid, Org 10172, in prevention of deep venous thrombosis. Thromb Res (1987) 0.75
The effect of sequential mestranol-norethisterone on the circulating lipid levels of pre- and post-menopausal women, and its possible significance. Postgrad Med J (1976) 0.75
Proceedings: Obstructive lipoprotein (LP-X) and liver disease. Clin Sci Mol Med (1974) 0.75
Cholestatic jaundice in infancy diagnosis, differential diagnosis and treatment. Aust Paediatr J (1976) 0.75
Existence of alkaline phosphatase-lipoprotein X complex questioned. Clin Chem (1981) 0.75
The influence of LP-X and other lipoproteins associated with hepatic dysfunction on the activity of lecithin:cholesterol acyltransferase. Biochim Biophys Acta (1976) 0.75
Heparin-induced thrombocytopenia: an under-diagnosed syndrome? Proceedings of a workshop held in London on 1 November 1996. Consensus overview. Platelets (1997) 0.75